Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Clinical Cancer Research, 06/25/09
Goel S et al. - Eribulin mesylate, given on days 1, 8, and 15 of a 28-day cycle, exhibits manageable tolerability at 1.0 mg/m2 with further dose escalation limited by neutropenia and fatigue.
Related Articles
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/16/09
Relevance Score: 65%
Diagnosis and Management of Adnexal Masses
American Family Physician, 10/16/09
Relevance Score: 65%
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Cancer Chemotherapy and Pharmacology, 11/12/09
Relevance Score: 64%
Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of solid pancreatic masses: the impact on patient-management strategy
Alimentary Pharmacology and Therapeutics, 10/23/09
Relevance Score: 64%
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Clinical Cancer Research, 10/15/09
Relevance Score: 64%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam
Pharmacoepidemiology and Drug Safety, 12/09/09
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor
Sponsor